Canadian biopharmaceutical company PlantForm, Thailand’s Baiya Phytopharm, and The DABOM, based in South Korea, signed a research collaboration agreement to develop plant-made artificial exosomes for improving therapeutics and drug delivery systems used to treat a variety of conditions, including cancer and neurodegenerative diseases.
The project, “Production of recombinant CD9 protein for generation of nanovesicles for microRNA delivery,” aims to synthesize and produce artificial exosomes that mimic natural exosomes, which play a key role in the body’s immune responses, inflammation, and other biological processes. CD9 is a gene-encoding protein that is commonly found on the surface of exosomes and may influence their ability to interact with other cells.
“Artificial exosomes have potentially far-reaching benefits to treat a wide range of diseases; however, there are some barriers to their application in new therapies. One of these limitations is the lack of process scalability. This project aims to help overcome that barrier,” said Don Stewart, PhD, PlantForm’s president and CEO.
The project, managed by Mun-Kyu Kim of Intro Global, combines the expertise of the three companies. PlantForm will design and synthesize the gene for CD9 using the vivoXPRESS® plant-based manufacturing platform. Baiya will express and purify recombinant CD9 in N. benthamiana plants using their BaiyaPharming
platform, while The DABOM will produce the artificial exosomes and compare them to natural exosomes.
“Artificial exosomes mimic natural exosomes that naturally occur in the body, which makes them highly biocompatible and less likely to activate an immune response,” noted Suthira Taychakhoonavudh, PhD, CEO of Baiya Phytopharm. “They can also be assembled to express specific proteins or peptides, allowing them to target specific cells or tissues.”
Artificial exosomes can be designed to encapsulate and deliver therapeutic payloads, including drugs, genes, and proteins. In addition to providing enhanced versatility and targeting, artificial exosomes can be produced at the scale required for clinical applications,” according to Hyo-Il Jung, PhD, CEO of The DABOM.
“Exosomes are natural cargo carriers that can efficiently deliver a variety of biomolecules, including DNA and RNA, for therapeutic purposes,” added Jung. “This project will compare the productivity and efficacy of artificial exosomes made with our system to existing natural exosomes. The aim is to conduct an in vitro proof of concept study of artificial exosomes for the delivery of a microRNA payload.”
The post PlantForm, Baiya Phytopharm, and The DABOM Collaborate on the Production of Artificial Exosomes appeared first on GEN - Genetic Engineering and Biotechnology News.
The project, “Production of recombinant CD9 protein for generation of nanovesicles for microRNA delivery,” aims to synthesize and produce artificial exosomes that mimic natural exosomes, which play a key role in the body’s immune responses, inflammation, and other biological processes. CD9 is a gene-encoding protein that is commonly found on the surface of exosomes and may influence their ability to interact with other cells.
“Artificial exosomes have potentially far-reaching benefits to treat a wide range of diseases; however, there are some barriers to their application in new therapies. One of these limitations is the lack of process scalability. This project aims to help overcome that barrier,” said Don Stewart, PhD, PlantForm’s president and CEO.
The project, managed by Mun-Kyu Kim of Intro Global, combines the expertise of the three companies. PlantForm will design and synthesize the gene for CD9 using the vivoXPRESS® plant-based manufacturing platform. Baiya will express and purify recombinant CD9 in N. benthamiana plants using their BaiyaPharming
“Artificial exosomes mimic natural exosomes that naturally occur in the body, which makes them highly biocompatible and less likely to activate an immune response,” noted Suthira Taychakhoonavudh, PhD, CEO of Baiya Phytopharm. “They can also be assembled to express specific proteins or peptides, allowing them to target specific cells or tissues.”
Artificial exosomes can be designed to encapsulate and deliver therapeutic payloads, including drugs, genes, and proteins. In addition to providing enhanced versatility and targeting, artificial exosomes can be produced at the scale required for clinical applications,” according to Hyo-Il Jung, PhD, CEO of The DABOM.
“Exosomes are natural cargo carriers that can efficiently deliver a variety of biomolecules, including DNA and RNA, for therapeutic purposes,” added Jung. “This project will compare the productivity and efficacy of artificial exosomes made with our system to existing natural exosomes. The aim is to conduct an in vitro proof of concept study of artificial exosomes for the delivery of a microRNA payload.”
The post PlantForm, Baiya Phytopharm, and The DABOM Collaborate on the Production of Artificial Exosomes appeared first on GEN - Genetic Engineering and Biotechnology News.